Roche Blinks But Is $93 Enough For Genentech Shareholders?
This article was originally published in The Pink Sheet Daily
Executive Summary
The $6.50 per share increase in Roche’s offer also includes an extension of the tender deadline to March 20.
You may also be interested in...
Roche Wins Genentech, But Will Biotech Employees Remain?
After eight months of haggling, Roche finally struck a deal to pay $95 a share for Genentech, an iconic biotech in which the drug maker already owns a 56 percent stake
Roche Wins Genentech, But Will Biotech Employees Remain?
After eight months of haggling, Roche finally struck a deal to pay $95 a share for Genentech, an iconic biotech in which the drug maker already owns a 56 percent stake
Roche Wins Genentech, But Will Biotech Employees Remain?
With a sweetened bid, the Swiss pharma gains the blessing of Genentech’s special committee, but whether the innovator’s valuable staffers sanction the union is an open question.